HPV-positive head and neck cancer patients fare better than HPV-negative patients

Feb 12, 2008

Head and neck cancer patients with HPV-positive tumors tend to survive longer and are more responsive to treatment compared with patients with HPV-negative tumors, according to a study published online February 12 in the Journal of the National Cancer Institute.

Human papillomavirus has been shown to be involved in the development of some head and neck cancers, particularly cancers of the upper throat, or oropharynx. Retrospective studies suggest that patients with HPV-positive tumors generally have a better prognosis than those patients with HPV-negative tumors, but these findings must be confirmed in clinical trials.

To examine the association between HPV infection and cancer prognosis, Maura Gillison, M.D., Ph.D., of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore and colleagues followed 96 patients with stage III or IV cancer of the oropharynx or larynx (voicebox). All of the patients were enrolled in the same phase II clinical trial and received the same treatment. The researchers collected data on the patients’ response to treatment and their survival times, as well as whether their tumors were HPV-positive or -negative.

Patients with HPV-positive tumors had higher response rates after chemoradiation therapy, compared to patients with HPV-negative tumors (84 percent vs. 57 percent), and their two-year overall survival rates were also higher (95 percent vs. 62 percent).

“Our data suggest that the risks and benefits of…therapies should be considered separately for HPV-positive and -negative patients,” the authors write.

Source: Journal of the National Cancer Institute

Explore further: Taking a look at the dark side of tourism in the Dominican Republic

add to favorites email to friend print save as pdf

Related Stories

'Stealth' nanoparticles could improve cancer vaccines

46 minutes ago

Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven't worked that well. Now, scientists have developed a new ...

New chip promising for tumor-targeting research

Sep 22, 2014

(Phys.org) —Researchers have developed a chip capable of simulating a tumor's "microenvironment" and plan to use the new system to test the effectiveness of nanoparticles and drugs that target cancer.

Wireless sensor transmits tumor pressure

Sep 20, 2014

The interstitial pressure inside a tumor is often remarkably high compared to normal tissues and is thought to impede the delivery of chemotherapeutic agents as well as decrease the effectiveness of radiation ...

Recommended for you

More HIV+ patients undergoing spinal fusion

Sep 25, 2014

(HealthDay)—More HIV-positive patients are undergoing spinal fusions, and these patients have higher rates of complications resulting from the procedures, according to a study published in the Sept. 15 ...

User comments : 0